Personalis (NASDAQ:PSNL) Shares Gap Down After Analyst Downgrade

Personalis, Inc. (NASDAQ:PSNL)’s share price gapped down before the market opened on Monday after Lake Street Capital downgraded the stock from a buy rating to a hold rating. The stock had previously closed at $15.39, but opened at $14.56. Lake Street Capital now has a $16.25 price target on the stock. Personalis shares last traded at $14.0830, with a volume of 3,002,381 shares trading hands.

A number of other analysts also recently issued reports on PSNL. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. BTIG Research cut their target price on shares of Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a report on Monday, May 11th. Morgan Stanley boosted their price target on shares of Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. Needham & Company LLC downgraded shares of Personalis from a “buy” rating to a “hold” rating in a research note on Monday. Finally, Wall Street Zen lowered shares of Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $14.25.

Insider Activity at Personalis

In other news, CEO Christopher M. Hall sold 100,000 shares of Personalis stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $15.08, for a total value of $1,508,000.00. Following the completion of the transaction, the chief executive officer owned 235,986 shares in the company, valued at approximately $3,558,668.88. The trade was a 29.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 4,982 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $14.00, for a total value of $69,748.00. Following the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at approximately $2,783,662. This represents a 2.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 435,032 shares of company stock worth $5,599,929 over the last three months. 4.20% of the stock is currently owned by insiders.

Personalis News Roundup

Here are the key news stories impacting Personalis this week:

• Positive Sentiment: The Tempus deal gives Personalis shareholders a clear cash/stock exit value at $16.25 per share, creating a takeover premium versus recent trading levels. Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
• Positive Sentiment: The acquisition validates Personalis’ MRD and cancer-monitoring technology, which Tempus said will strengthen its AI-enabled precision oncology platform and expand its cancer recurrence-testing capabilities. Tempus to acquire Personalis for $1.5 billion
• Neutral Sentiment: Several investor-rights law firms, including Halper Sadeh, Brodsky & Smith, Ademi, and Julie & Holleman, have launched investigations into whether the sale terms are fair to shareholders, which may add headline noise but does not change the deal economics. Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders?
• Neutral Sentiment: Analyst commentary has been mixed, with BTIG raising its price target to $16.25 while Needham downgraded the stock to hold, reflecting debate over valuation rather than a change in the merger terms. Analyst coverage references
• Negative Sentiment: Some market coverage notes that both PSNL and TEM traded lower after the deal announcement, suggesting investors may be concerned about execution risk, deal structure, or limited upside beyond the acquisition price. Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of PSNL. T. Rowe Price Investment Management Inc. raised its stake in shares of Personalis by 273.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock valued at $85,812,000 after acquiring an additional 7,896,714 shares during the period. Aberdeen Group plc boosted its stake in shares of Personalis by 36.1% during the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after purchasing an additional 861,948 shares during the period. Kennedy Capital Management LLC grew its holdings in Personalis by 196.2% during the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock valued at $12,617,000 after purchasing an additional 1,281,695 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Personalis by 1,332.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock valued at $11,531,000 after purchasing an additional 1,347,439 shares during the last quarter. Finally, Millennium Management LLC raised its position in Personalis by 11.0% in the 3rd quarter. Millennium Management LLC now owns 1,210,754 shares of the company’s stock worth $7,894,000 after purchasing an additional 120,027 shares during the period. 61.91% of the stock is owned by hedge funds and other institutional investors.

Personalis Trading Up 0.7%

The company has a market capitalization of $1.41 billion, a PE ratio of -13.18 and a beta of 2.24. The stock’s 50-day moving average is $11.24 and its two-hundred day moving average is $8.98.

Personalis (NASDAQ:PSNL) last announced its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The business had revenue of $15.47 million for the quarter, compared to analysts’ expectations of $14.48 million. Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. On average, equities research analysts forecast that Personalis, Inc. will post -1.07 EPS for the current fiscal year.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.